Vistagen Therapeutics IncNASDAQ:VTGN
- LAST PRICE3.0100
- TODAY'S CHANGE (%)0.0600 (2.0339%)
- Bid / Lots2.9600/ 2
- Ask / Lots3.1200/ 9
- Open / Previous Close2.9800 / 2.9500
- Day Range
- 52 Week Range
- Volume139,397
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VTGN |
|---|---|---|
| 09:32 ET | 388 | 2.98 |
| 09:38 ET | 100 | 2.96 |
| 09:39 ET | 5000 | 2.9988 |
| 09:48 ET | 100 | 2.9816 |
| 09:50 ET | 100 | 2.98 |
| 09:54 ET | 300 | 2.9801 |
| 09:56 ET | 281 | 2.99 |
| 09:57 ET | 2452 | 2.98 |
| 09:59 ET | 103 | 2.9859 |
| 10:12 ET | 100 | 2.96 |
| 10:14 ET | 2402 | 2.98 |
| 10:17 ET | 1881 | 2.975 |
| 10:19 ET | 1700 | 2.9622 |
| 10:28 ET | 5592 | 2.97 |
| 10:32 ET | 2099 | 2.97 |
| 10:33 ET | 300 | 2.98 |
| 10:35 ET | 100 | 2.98 |
| 10:42 ET | 388 | 2.987 |
| 10:50 ET | 100 | 2.98 |
| 10:53 ET | 100 | 2.9865 |
| 10:55 ET | 429 | 2.98 |
| 10:57 ET | 382 | 2.99 |
| 11:08 ET | 3128 | 2.99 |
| 11:18 ET | 858 | 2.975 |
| 11:20 ET | 1675 | 2.9657 |
| 11:24 ET | 12120 | 2.94 |
| 11:27 ET | 143 | 2.955 |
| 11:29 ET | 513 | 2.96 |
| 11:44 ET | 750 | 2.9665 |
| 11:45 ET | 300 | 2.961 |
| 11:54 ET | 106 | 2.9663 |
| 11:58 ET | 100 | 2.965 |
| 12:05 ET | 100 | 2.97 |
| 12:07 ET | 100 | 2.97 |
| 12:09 ET | 1000 | 2.9744 |
| 12:12 ET | 1000 | 2.977 |
| 12:18 ET | 300 | 2.97 |
| 12:27 ET | 190 | 2.962 |
| 12:39 ET | 100 | 2.97 |
| 12:48 ET | 545 | 2.9703 |
| 12:50 ET | 6000 | 2.9601 |
| 12:59 ET | 1009 | 2.97 |
| 01:15 ET | 100 | 2.96 |
| 01:26 ET | 1595 | 2.96 |
| 01:30 ET | 14197 | 2.955 |
| 01:32 ET | 1000 | 2.9521 |
| 01:35 ET | 8827 | 2.9699 |
| 01:48 ET | 4720 | 2.97 |
| 01:53 ET | 3367 | 2.98 |
| 01:55 ET | 1603 | 2.96 |
| 02:00 ET | 100 | 2.965 |
| 02:06 ET | 100 | 2.96 |
| 02:31 ET | 400 | 2.97 |
| 02:38 ET | 200 | 2.98 |
| 02:40 ET | 100 | 2.9704 |
| 02:44 ET | 375 | 2.98 |
| 03:00 ET | 2000 | 2.98 |
| 03:16 ET | 350 | 2.9795 |
| 03:18 ET | 100 | 2.98 |
| 03:25 ET | 127 | 2.98 |
| 03:30 ET | 200 | 2.98 |
| 03:34 ET | 20150 | 3.01 |
| 03:38 ET | 651 | 3.0172 |
| 03:54 ET | 2193 | 3.005 |
| 03:56 ET | 702 | 3.01 |
| 03:59 ET | 11819 | 3.01 |
Sep 23, 2024
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder, from 8:30AM ET on Monday Sep 23, 2024 by Dow Jones
8:30AM ET on Monday Sep 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vistagen Therapeutics Inc | 81.4M | -2.0x | --- |
Milestone Pharmaceuticals Inc | 79.9M | -1.5x | --- |
VolitionRX Ltd | 81.3M | -2.2x | --- |
Ovid Therapeutics Inc | 81.6M | -2.7x | --- |
Chimerix Inc | 82.1M | -1.0x | --- |
Sellas Life Sciences Group Inc | 81.1M | -1.3x | --- |
Company Information
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.
Contact Information
- Headquarters
- 343 ALLERTON AVENUESOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-577-3600
- Fax
- ---
Executives
- Independent Chairman of the Board
- Margaret Fitzpatrick
- Chief Executive Officer, Director
- Shawn Singh
- Chief Financial Officer
- Cynthia Anderson
- Chief Operating Officer
- Joshua Prince
- Senior Vice President - Investor Relations
- Mark Mcpartland
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $81.4M |
|---|---|
Revenue (TTM) | $970.4K |
Shares Outstanding | 27.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.78 |
EPS | $-1.53 |
Book Value | $4.23 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 83.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,931.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
